Linderalactone
Based on 3 publication(s) in Google Scholar
Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC50 of 15 µM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.96%
- CAS No.: 728-61-0
- Formule: C15H16O3
- Masse moléculaire:244.29
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Macrocyclic Compound Library
HY-L041
-
Terpenoids Library
HY-L056
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Linderalactone
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
98 μM
Compound: linderalactone
|
Hepatoprotective activity in human HepG2 cells assessed as inhibition of H2O2- induced oxidative damage after 3 hrs by leucocrstal violet dye treated 1 hr before H2O2 challenge
Hepatoprotective activity in human HepG2 cells assessed as inhibition of H2O2- induced oxidative damage after 3 hrs by leucocrstal violet dye treated 1 hr before H2O2 challenge
|
[PMID: 19639966] |
| Neutrophil | IC50 |
3.21 μg/mL
Compound: 10
|
Antiinflammatory activity in human neutrophils assessed as inhibition of dihydrocytochalasin-induced superoxide anion production
Antiinflammatory activity in human neutrophils assessed as inhibition of dihydrocytochalasin-induced superoxide anion production
|
[PMID: 22148193] |
| Neutrophil | IC50 |
8.48 μg/mL
Compound: 10
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-induced superoxide anion production
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-induced superoxide anion production
|
[PMID: 22148193] |
Linderalactone (0-100 μM; 24 hours; A549 cells) treatment inhibits the growth of A549 cells concentration-dependently. The IC50 of linderalactone is 15 μM[1].
?
Linderalactone (7.5-30 μM; A549 cells) treatment induces apoptosis in A549 cells in a dose-dependent manner[1].
?
Linderalactone (7.5-30 μM; 24 hours; A549 cells) treatment induces G2/M cell cycle arrest of A549 cells dose-dependently[1].
?
Linderalactone (7.5-30 μM; A549 cells) inhibits the expression of STAT1, JAK1 and JAK2. Linderalactone could also inhibit the phosphorylation of pSTAT1, pSTAT-2, pJAK1 and pJAk2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Lung cancer A549 cells
-
Concentration:0 μM, 1.6 μM, 3.2 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM
-
Incubation Time:24 hours
-
Result:Inhibited the growth of A549 cells concentration-dependently.
-
Cell Line:Lung cancer A549 cells
-
Concentration:7.5 μM, 15 μM, 30 μM
-
Incubation Time:
-
Result:Induced apoptosis in A549 cells in a dose-dependent manner.
-
Cell Line:Lung cancer A549 cells
-
Concentration:7.5 μM, 15 μM, 30 μM
-
Incubation Time:24 hours
-
Result:Induced G2/M cell cycle arrest.
-
Cell Line:Lung cancer A549 cells
-
Concentration:7.5 μM, 15 μM, 30 μM
-
Incubation Time:
-
Result:Inhibited the JAK/STAT pathway in A549 cells.
Chemical Information
-
CAS No. 728-61-0
-
Appearance Solid
-
Masse moléculaire 244.29
-
Formule C15H16O3
-
Color White to yellow
-
SMILES
O=C1C2=C[C@@](C3=C(OC=C3C)C/C(C)=C/CC2)([H])O1
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
IL-33/TGF-β/IL-4-induced bone marrow-derived DC9 subset promotes Th9 differentiation and allergic airway inflammation. [Abstract]2026 Jun 4;45(6):117519. PMID: 42247295 -
Int Immunopharmacol
Linderalactone mitigates diabetic cardiomyopathy in mice via suppressing the MAPK/ATF6 pathway. [Abstract]2023 Nov;124(Pt B):110984. PMID: 37757635 -
J Diabetes Investig
Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/CARD9/IRF5/NF-κB pathway. [Abstract]2026 Mar;17(3):395-410. PMID: 41504208
Solvant et solubilité
DMSO : 33.33 mg/mL (136.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (10.23 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0935 mL | 20.4675 mL | 40.9350 mL | 102.3374 mL |
| 5 mM | 0.8187 mL | 4.0935 mL | 8.1870 mL | 20.4675 mL | |
| 10 mM | 0.4093 mL | 2.0467 mL | 4.0935 mL | 10.2337 mL | |
| 15 mM | 0.2729 mL | 1.3645 mL | 2.7290 mL | 6.8225 mL | |
| 20 mM | 0.2047 mL | 1.0234 mL | 2.0467 mL | 5.1169 mL | |
| 25 mM | 0.1637 mL | 0.8187 mL | 1.6374 mL | 4.0935 mL | |
| 30 mM | 0.1364 mL | 0.6822 mL | 1.3645 mL | 3.4112 mL | |
| 40 mM | 0.1023 mL | 0.5117 mL | 1.0234 mL | 2.5584 mL | |
| 50 mM | 0.0819 mL | 0.4093 mL | 0.8187 mL | 2.0467 mL | |
| 60 mM | 0.0682 mL | 0.3411 mL | 0.6822 mL | 1.7056 mL | |
| 80 mM | 0.0512 mL | 0.2558 mL | 0.5117 mL | 1.2792 mL | |
| 100 mM | 0.0409 mL | 0.2047 mL | 0.4093 mL | 1.0234 mL |
Linderalactone Related Classifications
HY-N0781 Related Classifications
Powered by Bioz